1
|
Nakase Y, Hamada A, Obayashi F, Kitamura N, Hata T, Yamamoto T, Okamoto T. Establishment of induced pluripotent stem cells derived from patients and healthy siblings of a nevoid basal cell carcinoma syndrome family. In Vitro Cell Dev Biol Anim 2023; 59:395-400. [PMID: 37460876 PMCID: PMC10374668 DOI: 10.1007/s11626-023-00778-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Accepted: 06/06/2023] [Indexed: 07/29/2023]
Abstract
It is known that a nevoid basal cell carcinoma syndrome (NBCCS) is characterized by a combination of developmental abnormalities and a predisposition to form various tumors. Although it is possible to create disease models via gene editing, there are significant potential problems with this approach such as off-target mutations and differences in SNPs. On the other hand, since disease families share common SNPs, research using iPSCs derived from both patients and healthy siblings of the same disease family is very important. Thus, establishment of induced pluripotent stem cells derived from patients and healthy siblings of the same NBCCS family will be of great importance to study the etiology of this disease and to develop therapeutics. In this study, we generated hiPSCs using peripheral blood mononuclear cells derived from the patients and healthy siblings of familial NBCCS with the novel mutation in PTCH1_c.3298_3299insAAG in the feeder- and serum-free culture conditions using SeVdp. In addition, disease-specific hiPSCs such as those expressing the PTCH1_c.3298_3299insAAG mutation could be powerful tools for revealing the genotype-phenotype relationship and pathogenicity of NBCCS.
Collapse
Affiliation(s)
- Yoji Nakase
- Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-Ku, Hiroshima-City, Hiroshima, 734-8553, Japan
| | - Atsuko Hamada
- Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-Ku, Hiroshima-City, Hiroshima, 734-8553, Japan.
| | - Fumitaka Obayashi
- Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-Ku, Hiroshima-City, Hiroshima, 734-8553, Japan
| | - Naoya Kitamura
- Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Kochi, Japan
| | - Tsuyoshi Hata
- Department of Oral Surgery, Kawasaki Medical School, Okayama, Japan
- Present affiliation: Kondo Dental Clinic, Medical Corporation Mutsumikai, Okayama, Japan
| | - Tetsuya Yamamoto
- Department of Oral and Maxillofacial Surgery, Kochi Medical School, Kochi University, Kochi, Japan
| | - Tetsuji Okamoto
- Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-Ku, Hiroshima-City, Hiroshima, 734-8553, Japan
- School of Medical Sciences, University of East Asia, Shimonoseki, Japan
| |
Collapse
|
2
|
Eldecalcitol (ED-71)-induced exosomal miR-6887-5p suppresses squamous cell carcinoma cell growth by targeting heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1). In Vitro Cell Dev Biol Anim 2020; 56:222-233. [PMID: 32185608 DOI: 10.1007/s11626-020-00440-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Accepted: 02/25/2020] [Indexed: 12/14/2022]
Abstract
Heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) was purified from A431 cell-conditioned media based on its capacity to bind to fibroblast growth factor 1 and 2 (FGF-1 and FGF-2). HBp17/FGFBP-1 has been observed to induce the tumorigenic potential of epithelial cells and is highly expressed in oral cancer cell lines and tissues. HBp17/FGFBP-1 is also recognized as a pro-angiogenic molecule as a consequence of its interaction with FGF-2. We have previously reported that Eldecalcitol (ED-71), an analog of 1α,25(OH)2D3, downregulated the expression of HBp17/FGFBP-1 and inhibited the proliferation of squamous cell carcinoma (SCC) cells in vitro and in vivo through NF-κb inhibition. To explore the possibility of microRNA (miRNA) control of HBp17/FGFBP-1, we analyzed exosomal miRNAs from medium conditioned by A431 cells treated with ED-71. Microarray analysis revealed that 12 exosomal miRNAs were upregulated in ED-71-treated A431 cells. Among them, miR-6887-5p was identified to have a predicted mRNA target matching the 3' untranslated region (3'-UTR) of HBp17/FGFBP-1. The 3'-UTR of HBp17/FGFBP-1 was confirmed to be a direct target of miR-6887-5p in SCC/OSCC cells, as assessed with a luciferase reporter assay. Functional assessment revealed that overexpression of miR-6887-5p in SCC/OSCC cells inhibited cell proliferation and colony formation in vitro, and inhibited tumor growth in vivo compared with control. In conclusion, our present study supports a novel anti-cancer mechanism involving the regulation of HBp17/FGFBP-1 function by exosomal miR-6887-5p in SCC/OSCC cells, which has potential utility as a miRNA-based cancer therapy.
Collapse
|
3
|
Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy. Oncotarget 2018; 7:83378-83391. [PMID: 27825128 PMCID: PMC5347776 DOI: 10.18632/oncotarget.13092] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Accepted: 10/19/2016] [Indexed: 01/01/2023] Open
Abstract
High grade neuroepithelial tumor of the central nervous system with BCOR alteration (CNS HGNET-BCOR) is a recently described new tumor entity with a dismal prognosis. The objective of this study was to identify and validate pathways deregulated in CNS HGNET-BCOR as basis for targeted therapy approaches. We characterized the BCOR alteration in a pediatric patient with CNS HGNET-BCOR diagnosis by Sanger sequencing and demonstrated an elevated BCOR expression by qRT-PCR and western blot. By whole transcriptome sequencing and Ingenuity Pathway Analysis, we identified the activation of the Sonic Hedgehog (SHH) and of the WNT signaling pathway in two different regions of the primary tumor and of one inoculation metastasis compared to normal brain. We validated the activation of the SHH and of the WNT pathway by qRT-PCR analysis of GLI1 and AXIN2 respectively. GLI1 and AXIN2 were upregulated in the primary tumor and in two inoculation metastases compared to normal brain. Mutational analysis of SMO, PTCH1 and SUFU, three key components of the SHH pathway, revealed a Single Nucleotide Polymorphism (SNP) in PTCH1 (rs357564). We tested the effect of the GLI-inhibitor arsenic trioxide (ATO) on a short-term cell culture isolated from the metastasis. ATO was able to reduce the viability of the cells with an IC50 of 1.3 μM. In summary, these results provide functional evidence of altered BCOR expression and homogeneous coactivation of both the SHH and WNT signaling pathways, building the basis for potential novel therapeutic approaches for patients with a CNS HGNET-BCOR diagnosis.
Collapse
|
4
|
Fumagalli G, Stella B, Pastushenko I, Ricci F, Christodoulou MS, Damia G, Mazza D, Arpicco S, Giannini C, Morosi L, Dosio F, Sotiropoulou PA, Passarella D. Heteronanoparticles by self-Assembly of Doxorubicin and Cyclopamine Conjugates. ACS Med Chem Lett 2017; 8:953-957. [PMID: 28947943 PMCID: PMC5601370 DOI: 10.1021/acsmedchemlett.7b00262] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Accepted: 08/01/2017] [Indexed: 11/29/2022] Open
Abstract
The preparation of heteronanoparticles (NPs) with doxorubicin (DOXO) and cyclopamine (CYP) conjugates is presented. Biological evaluation on A431 cell lines confirms the maintenance of the activity of the parental drugs. The in vivo study shows that self-assembled NPs reduce tumor growth and toxicity of chemotherapy.
Collapse
Affiliation(s)
- Gaia Fumagalli
- Dipartimento
di Chimica, Università degli Studi
di Milano, Milano 20133, Italy
| | - Barbara Stella
- Dipartimento
di Scienza e Tecnologia del Farmaco, Università
degli Studi di Torino, Torino 10125, Italy
| | - Ievgenia Pastushenko
- Interdisciplinary
Research Institute (IRIBHM), Université
Libre de Bruxelles (ULB), Brussels 1070, Belgium
| | - Francesca Ricci
- Laboratory
of Molecular Pharmacology, IRCCS-Istituto
di Ricerche Farmacologiche Mario Negri, Milano 20156, Italy
| | | | - Giovanna Damia
- Laboratory
of Molecular Pharmacology, IRCCS-Istituto
di Ricerche Farmacologiche Mario Negri, Milano 20156, Italy
| | - Davide Mazza
- Centro
di Imaging Sperimentale San Raffaele Scientific Institute, Milano 20132, Italy
- Centro
Europeo di Nanomedicina, Milano 20133, Italy
| | - Silvia Arpicco
- Dipartimento
di Scienza e Tecnologia del Farmaco, Università
degli Studi di Torino, Torino 10125, Italy
| | - Clelia Giannini
- Dipartimento
di Chimica, Università degli Studi
di Milano, Milano 20133, Italy
| | - Lavinia Morosi
- Laboratory
of Cancer Pharmacology, IRCCS-Istituto di
Ricerche Farmacologiche Mario Negri, Milano 20156, Italy
| | - Franco Dosio
- Dipartimento
di Scienza e Tecnologia del Farmaco, Università
degli Studi di Torino, Torino 10125, Italy
| | - Panagiota A. Sotiropoulou
- Interdisciplinary
Research Institute (IRIBHM), Université
Libre de Bruxelles (ULB), Brussels 1070, Belgium
| | - Daniele Passarella
- Dipartimento
di Chimica, Università degli Studi
di Milano, Milano 20133, Italy
| |
Collapse
|
5
|
Shintani T, Takatsu F, Rosli SNZ, Usui E, Hamada A, Sumi K, Hayashido Y, Toratani S, Okamoto T. Eldecalcitol (ED-71), an analog of 1α,25(OH) 2D 3, inhibits the growth of squamous cell carcinoma (SCC) cells in vitro and in vivo by down-regulating expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) and FGF-2. In Vitro Cell Dev Biol Anim 2017; 53:810-817. [PMID: 28710602 DOI: 10.1007/s11626-017-0183-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Accepted: 06/21/2017] [Indexed: 10/19/2022]
Abstract
Heparin-binding protein 17 (HBp17)/fibroblast growth factor-binding protein-1 (FGFBP-1) was first purified from medium conditioned by A431 cells for its capacity to bind to fibroblast growth factors 1 and 2 (FGF-1 and -2). Among FGF family members, FGF-2 is a potent mitogen for various cell types, including vascular endothelial cells, fibroblasts, and cancer cells such as oral squamous cell carcinoma (OSCC) cells. Besides being well known in bone metabolism, the active form of vitamin D3, i.e., 1α,25(OH)2D3 (1,25D3), was reported to have protective effects for heart disease and cancer. Previously, we reported that 1,25D3 inhibited HBp17/FGFBP-1 expression in OSCC cell lines through NF-κB inhibition (IκBα activation) and resulted in the inactivation of FGF-2. In this study, we examined the potential anti-tumor effect of ED-71, an analog of 1α,25(OH)2D3, for squamous cell carcinoma cells in vitro and in vivo. The cell lines used were OSCC cell lines (NA-HO-1-n-1 and UE-HO-1-u-1), established from oral cancer patients in our laboratory, and an epidermoid carcinoma/SCC cell line (A431). The growth assay in serum-free culture revealed that ED-71 inhibited the growth of the cancer cell lines in a dose-dependent manner. In addition, ED-71 suppressed HBp17/FGFBP-1 expression by inhibiting the NF-κB pathway as did 1,25D3. Furthermore, a luciferase reporter assay revealed that the promoter activity of HBp17/FGFBP-1 (region between -217 and +61) was down-regulated by ED-71. Oral administration of ED-71 significantly inhibited the growth of A431-derived tumors in athymic nude mice. Immunohistochemical analysis revealed that the expression of HBp17/FGFBP-1, FGF-2, CD31, and Ki-67 in the tumors of ED71-treated group was down-regulated in comparison to control. These results suggest that ED-71 possesses potential anti-tumor activity for SCCs both in vitro and in vivo. This compound may act directly on the tumor cells or on endothelial cells by modulating the tumor microenvironment.
Collapse
Affiliation(s)
- T Shintani
- Center of Oral Clinical Examination, Hiroshima University Hospital, Hiroshima, Japan
| | - F Takatsu
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - S N Z Rosli
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Graduate Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan
| | - E Usui
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - A Hamada
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - K Sumi
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Graduate Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan
| | - Y Hayashido
- Oral Maxillofacial Surgery, Hiroshima University Hospital, Hiroshima, Japan
| | - S Toratani
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Graduate Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan
| | - Tetsuji Okamoto
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Graduate Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, 734-8553, Japan.
| |
Collapse
|
6
|
Shintani T, Rosli SNZ, Takatsu F, Choon YF, Hayashido Y, Toratani S, Usui E, Okamoto T. Eldecalcitol (ED-71), an analog of 1α,25-dihydroxyvitamin D3 as a potential anti-cancer agent for oral squamous cell carcinomas. J Steroid Biochem Mol Biol 2016; 164:79-84. [PMID: 26444325 DOI: 10.1016/j.jsbmb.2015.09.043] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2015] [Revised: 09/28/2015] [Accepted: 09/29/2015] [Indexed: 11/26/2022]
Abstract
We have previously reported that 1,25(OH)2D3 inhibits NF-κB activity and thus inhibits growth of OSCC cells in serum-free culture and down-regulates HBp17/FGFBP-1 expression, which is important for cancer cell growth and angiogenesis. Here, we have investigated the effects of ED-71, an analog of vitamin D3 (VD) on OSCC cell lines in serum-free culture. It is known that ED-71 has a stronger inhibitory effect on bone resorption compared to VD and other VD analogs. To the best of our knowledge, there was no report examining the potential of ED-71 as an anti-cancer agent for OSCC. We found that ED-71 is able to inhibit the growth of cancer cell lines at a concentration of hundred times lower than calcitriol. As Cyp24A1 was reportedly induced in cancer cells, we measured the expression of CYP24A1 in OSCC cell lines (NA and UE), A431 epidermoid carcinoma and normal fibroblast cell (gfi) in serum-free culture. As a result, CYP24A1 mRNA and the protein expression in the OSCC cells treated with ED-71 increased in a dose-dependent manner. However, in vivo experiment, in which the A431 cells were implanted in mice, tumor formation was reduced by the ED-71 treatment with no significant difference between Cyp24A1 expression in the tumors of ED-71-treated and control group, as analyzed by western blotting and immunohistochemistry. These results suggest that ED-71 is a potential anti-cancer agent for OSCC.
Collapse
Affiliation(s)
- T Shintani
- Center of Oral Clinical Examination, Hiroshima University Hospital, Japan
| | - S N Z Rosli
- Department of Molecular Oral Medicine & Maxillofacial Surgery, Graduate School of Biomedical & Health Sciences, Japan; Oral Cancer Research & Coordinating Center, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
| | - F Takatsu
- Department of Molecular Oral Medicine & Maxillofacial Surgery, Graduate School of Biomedical & Health Sciences, Japan
| | - Y F Choon
- Oral Cancer Research & Coordinating Center, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia
| | - Y Hayashido
- Oral Maxillofacial Surgery, University Hospital, Japan
| | - S Toratani
- Department of Molecular Oral Medicine & Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan
| | - E Usui
- Oral Maxillofacial Surgery, University Hospital, Japan
| | - T Okamoto
- Department of Molecular Oral Medicine & Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
| |
Collapse
|
7
|
Rosli SNZ, Shintani T, Hayashido Y, Toratani S, Usui E, Okamoto T. 1α,25OH2D3 down-regulates HBp17/FGFBP-1 expression via NF-κB pathway. J Steroid Biochem Mol Biol 2013; 136:98-101. [PMID: 23104116 DOI: 10.1016/j.jsbmb.2012.10.011] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2012] [Revised: 10/07/2012] [Accepted: 10/11/2012] [Indexed: 10/27/2022]
Abstract
The heparin binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1, GenBank accession no. NP-005121) has been reported to enhance angiogenesis as well as promotes tumor growth in vivo. Furthermore, this molecule was found to be highly expressed in the tissue and cell lines of oral squamous cell carcinoma (OSCC). 1α,25(OH)2D3 is used to study its potential to curb the expression of HBp17/FGFBP-1 in cancer cells. Consequently, we found that HBp17/FGFBP-1 mRNA and protein levels were significantly down-regulated. In this present study, we show that this event takes place via the NF-κB pathway since mRNA and protein levels of this pathway regulator, IκBα, were found to be significantly up-regulated. Furthermore, the promoter activity of HBp17/FGFBP-1 (region between -217 and +61) measured by a luciferase reporter assay was down-regulated following treatment. Silencing of VDR with siRNA showed the effect of 1α,25(OH)2D3 on HBp17/FGFBP-1. Based on these findings, we concluded that 1α,25(OH)2D3 down-regulated HBp17/FGFBP-1 expression via NF-κB. This article is part of a Special Issue entitled 'Vitamin D Workshop'.
Collapse
Affiliation(s)
- S N Z Rosli
- Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Frontier Medical Sciences, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan
| | | | | | | | | | | |
Collapse
|
8
|
Lim CB, Prêle CM, Cheah HM, Cheng YY, Klebe S, Reid G, Watkins DN, Baltic S, Thompson PJ, Mutsaers SE. Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma. PLoS One 2013; 8:e66685. [PMID: 23826113 PMCID: PMC3691204 DOI: 10.1371/journal.pone.0066685] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2013] [Accepted: 05/08/2013] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND The Hedgehog (HH) signaling pathway is critical for embryonic development and adult homeostasis. Recent studies have identified regulatory roles for this pathway in certain cancers with mutations in the HH pathway genes. The extent to which mutations of the HH pathway genes are involved in the pathogenesis of malignant mesothelioma (MMe) is unknown. METHODOLOGY/PRINCIPAL FINDINGS Real-time PCR analysis of HH pathway genes PTCH1, GLI1 and GLI2 were performed on 7 human MMe cell lines. Exon sequencing of 13 HH pathway genes was also performed in cell lines and human MMe tumors. In silico programs were used to predict the likelihood that an amino-acid substitution would have a functional effect. GLI1, GLI2 and PTCH1 were highly expressed in MMe cells, indicative of active HH signaling. PTCH1, SMO and SUFU mutations were found in 2 of 11 MMe cell lines examined. A non-synonymous missense SUFU mutation (p.T411M) was identified in LO68 cells. In silico characterization of the SUFU mutant suggested that the p.T411M mutation might alter protein function. However, we were unable to demonstrate any functional effect of this mutation on Gli activity. Deletion of exons of the PTCH1 gene was found in JU77 cells, resulting in loss of one of two extracellular loops implicated in HH ligand binding and the intracellular C-terminal domain. A 3-bp insertion (69_70insCTG) in SMO, predicting an additional leucine residue in the signal peptide segment of SMO protein was also identified in LO68 cells and a MMe tumour. CONCLUSIONS/SIGNIFICANCE We identified the first novel mutations in PTCH1, SUFU and SMO associated with MMe. Although HH pathway mutations are relatively rare in MMe, these data suggest a possible role for dysfunctional HH pathway in the pathogenesis of a subgroup of MMe and help rationalize the exploration of HH pathway inhibitors for MMe therapy.
Collapse
Affiliation(s)
- Chuan Bian Lim
- Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, Department of Medicine, School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia
| | - Cecilia M. Prêle
- Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, Department of Medicine, School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia
- Centre for Cell Therapy and Regenerative Medicine, School of Medicine and Pharmacology and Western Australian Institute for Medical Research, University of Western Australia, Crawley, WA, Australia
| | - Hui Min Cheah
- Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, Department of Medicine, School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia
| | - Yuen Yee Cheng
- Asbestos Diseases Research Institute (ADRI), University of Sydney, Sydney, NSW, Australia
| | - Sonja Klebe
- Department of Anatomical Pathology, SA Pathology and Flinders University, Flinders Medical Centre, Adelaide, Australia
| | - Glen Reid
- Asbestos Diseases Research Institute (ADRI), University of Sydney, Sydney, NSW, Australia
| | - D. Neil Watkins
- Centre for Cancer Research, Monash Institute for Medical Research, Monash University, Melbourne, Victoria, Australia
| | - Svetlana Baltic
- Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, Department of Medicine, School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia
| | - Philip J. Thompson
- Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, Department of Medicine, School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia
| | - Steven E. Mutsaers
- Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, Department of Medicine, School of Medicine and Pharmacology, University of Western Australia, Crawley, WA, Australia
- Centre for Cell Therapy and Regenerative Medicine, School of Medicine and Pharmacology and Western Australian Institute for Medical Research, University of Western Australia, Crawley, WA, Australia
- * E-mail:
| |
Collapse
|
9
|
|
10
|
Abstract
An increasing progress on the role of Hedgehog (Hh) signaling for carcinogenesis has been achieved since the link of Hh pathway to human cancer was firstly established. In particular, the critical role of Hh signaling in the development of Basal cell carcinoma (BCC) has been convincingly demonstrated by genetic mutation analyses, mouse models of BCCs, and successful clinical trials of BCCs using Hh signaling inhibitors. In addition, the Hh pathway activity is also reported to be involved in the pathogenesis of Squamous Cell Carcinoma (SCC), melanoma and Merkel Cell Carcinoma. These findings have significant new paradigm on Hh signaling transduction, its mechanisms in skin cancer and even therapeutic approaches for BCC. In this review, we will summarize the major advances in the understanding of Hh signaling transduction, the roles of Hh signaling in skin cancer development, and the current implications of "mechanism-based" therapeutic strategies.
Collapse
Affiliation(s)
- Chengxin Li
- Department of Dermatology, Xijing hospital, Fourth Military Medical University, Xi’an 710032, China
| | - Sumin Chi
- Department of Physiology, Fourth Military Medical University, Xi’an 710032, China
| | - Jingwu Xie
- Wells Center for Pediatric Research, Division of Hematology and Oncology, Department of Pediatrics, Indiana University Simon Cancer Center, Indiana University, Indianapolis, Indiana 46202, USA
| |
Collapse
|
11
|
Kudo Y, Tsunematsu T, Takata T. Oncogenic role of RUNX3 in head and neck cancer. J Cell Biochem 2011; 112:387-93. [PMID: 21268058 DOI: 10.1002/jcb.22967] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Cumulative evidences show that Runt-related transcription factor 3 (RUNX3) has a tumor suppressive role in various cancers. In particular, RUNX3 appears to be an important component of the transforming growth factor-β (TGF-β)-induced tumor suppression pathway. Contrary to reports on this tumor suppressive role of RUNX3, RUNX3 can also function as an oncogene when overexpressed. Recently, we found that RUNX3 overexpression was frequently observed and was well correlated with malignant behaviors in head and neck cancer, which is one of the most common types of human cancer. Moreover, it has been revealed that RUNX3 overexpression promoted cell growth and inhibited apoptosis in head and neck cancer cells. This review introduces the oncogenic role of RUNX3 in certain types of cancer including head and neck cancer.
Collapse
Affiliation(s)
- Yasusei Kudo
- Division of Frontier Medical Science, Department of Oral and Maxillofacial Pathobiology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
| | | | | |
Collapse
|
12
|
Nakamura M, Kakuda T, Qi J, Hirata M, Shintani T, Yoshioka Y, Okamoto T, Oba Y, Nakamura H, Ojika M. Novel relationship between the antifungal activity and cytotoxicity of marine-derived metabolite xestoquinone and its family. Biosci Biotechnol Biochem 2006; 69:1749-52. [PMID: 16195594 DOI: 10.1271/bbb.69.1749] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Xestoquinone and related metabolites (the xestoquinone family) occur in marine sponges and are known to show a variety of biological activities. In this study, the first comprehensive evaluation of antifungal activity was performed for xestoquinone and nine natural and unnatural analogues in comparison with their cytotoxicity. The cytotoxicity against two human squamous cell carcinoma cell lines, A431 and Nakata, indicated that the terminal quinone structure of the polycyclic molecules was important (xestoquinone, etc.) and that the presence of a ketone group at C-3 of the opposite terminus dramatically diminished the activity (halenaquinone, etc.). In contrast, a ketone group at C-3 enhanced the antifungal activity against the plant pathogen, Phytophthora capsici, regardless of the presence of a quinone moiety. The cytotoxicity and antifungal activity of the xestoquinone family were negatively correlated with each other.
Collapse
Affiliation(s)
- Mitsuhiro Nakamura
- Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Koike C, Mizutani T, Ito T, Shimizu Y, Yamamichi N, Kameda T, Michimukai E, Kitamura N, Okamoto T, Iba H. Introduction of wild-type patched gene suppresses the oncogenic potential of human squamous cell carcinoma cell lines including A431. Oncogene 2002; 21:2670-8. [PMID: 11965540 DOI: 10.1038/sj.onc.1205370] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2001] [Revised: 01/24/2002] [Accepted: 01/31/2002] [Indexed: 11/08/2022]
Abstract
Defects in a developmental signaling pathway involving the mammalian homologue of the Drosophila segment polarity gene, patched are associated with human tumors such as basal cell carcinoma, medulloblastoma and squamous cell carcinoma. Loss of heterozygosity (LOH) in some of these tumor cells suggests that patched functions as a tumor suppressor gene. To evaluate the biological significance of patched mutations in human sporadic tumor cells, we constructed a VSV-G pseudotyped retrovirus vector carrying the wild-type patched gene and transduced it into two human squamous cell carcinoma (SCC) cell lines, A431 and KA, that express only mutant patched mRNA. When SSC cells were transduced with Ptc virus, colony forming activity in soft agar was drastically reduced and these cells recovered anchorage independent growth when Sonic hedgehog (Shh), the ligand of Patched (Ptc), was added into the soft agar culture. Expression of exogenous patched, however, had no effect on anchorage independent growth of Ras-transformed NIH3T3 cells or SCC cell line, NA, which expresses wild-type patched mRNA. Cyclopamine, a specific inhibitor of the Shh/Ptc/Smo signaling pathway, efficiently suppressed anchorage independent growth of A431 and KA cells. These results indicate that loss of patched function plays a major role in the acquisition of oncogenic potential in these SCCs and further that Ptc virus would be an effective reagent for suppressing tumorigenicity of such SCCs.
Collapse
Affiliation(s)
- Chika Koike
- Department of Microbiology and Immunology, Division of Host-Parasite Interaction, Institute of Medical Science, University of Tokyo, 4-6-1 Shirokanedai Minato-ku Tokyo 108-8639, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|